|
2024
|
Invention
|
Ido/tdo inhibitor.
A compound of formula (I) given below or a pharmaceutically acceptable salt o... |
|
2022
|
Invention
|
Lymphocyte function promoter, agent for combination use with therapeutic agent for lymphocyte-med... |
|
2020
|
Invention
|
Rna methyltransferase inhibitor, screening method therefor, anti-cancer agent efficacy assessment... |
|
|
Invention
|
Immune checkpoint inhibitor combination therapy using quinoline carboxamide derivative.
Provided... |
|
|
Invention
|
Immune checkpoint inhibitor combination therapy using quinoline carboxamide derivative. Provided ... |
|
2019
|
Invention
|
Cancer combination therapy using quinoline carboxamide derivative.
Provided is a method for usin... |
|
|
Invention
|
Cancer combination therapy using quinoline carboxamide derivative. Provided is a method for using... |
|
2018
|
Invention
|
Ido/tdo inhibitor. 6 represents, for example, a substituted or unsubstituted aryl group].
|
|
|
Invention
|
Ido/tdo inhibitor. Provided is a compound represented by formula (I) or a pharmaceutically accept... |
|
2017
|
Invention
|
Agent for overcoming immunosuppression and use thereof. To provide an agent for overcoming immuno... |
|
|
Invention
|
Immunosuppression weaning agent and use thereof. Provided is an immunosuppression weaning agent w... |
|
2016
|
Invention
|
Anti-norovirus composition and utilization thereof. Provided are: a composition having an excelle... |
|
2014
|
Invention
|
Proteasome-inhibiting compound. The objective of the present invention is to provide a novel comp... |
|
|
Invention
|
Eg5 inhibitor. Compared to a traditional Eg5 (KSP: kinesin spindle protein) inhibitor, this water... |
|
2013
|
Invention
|
Novel cysteine compound and salt thereof. The purpose of the present invention is to provide a no... |
|
|
Invention
|
Affinity ligand for antibody purification. The issue of providing molecules which specifically b... |
|
2010
|
Invention
|
1,3,4-oxadiazole-2-carboxamide compound. Disclosed is a 1,3,4-oxadiazole-2-carboxamide compound w... |
